Skip to main content

Table 3 Serum protein levels in lung cancer patients and COPD patients. LCCOPD –lung cancer with COPD. LConly –lung cancer with and without COPD

From: Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease

MANCOVA MANCOVA ANOVA
Protein COPD (n = 42) vs LC (n = 207) BC-sign COPD / LConly / LCcopd BC-sign COPD vs LCcopd COPD vs LConly LCcopd vs LConly
OPG p < 0.001 Sign. p < 0.001 Sign. p < 0.001 p < 0.001 ns
PTX3 p = 0.001 Sign. p = 0.002 Sign. p = 0.04 p = 0.001 ns
Axl p < 0.001 Sign. p < 0.001 Sign. p < 0.001 p = 0.002 ns
CXCL16 p = 0.019 ns p = 0.005 ns ns p = 0.002 p = 0.023
Alcam (CD166) p < 0.001 Sign. p < 0.001 Sign. p < 0.001 p < 0.001 ns
sCD163 p = 0.001 Sign. p = 0.001 Sign. ns p = 0.01 ns
CD147 p < 0.001 Sign. p < 0.001 Sign. p < 0.001 p < 0.001 ns
Endostatin ns ns p = 0.005 ns ns ns p = 0.033
Cats p = 0.002 Sign. p = 0.004 ns p = 0.029 p = 0.004 ns
CRP ns ns p = 0.004 ns p = 0.018 ns p = 0.001
DLL1 p < 0.001 Sign. p < 0.001 Sign. p < 0.001 p < 0.001 ns
  1. ANOVA and MANCOVA analyses comparing circulating protein levels in patients with COPD and patients with lung cancer with and without COPD. One-way MANCOVA was performed on two groups (COPD and Lung cancer with and without COPD), and on three groups (COPD, lung cancer with COPD and lung cancer without COPD). One-way ANOVA was conducted to explore the differences in the levels of proteins between the three groups; COPD (n = 42), lung cancer with COPD (n = 116) and lung cancer without COPD (n = 92). Multiple testing is controlled for by Bonferroni correction. Only significant markers are shown